mRNA新冠疫苗接种后心肌炎与病毒性心肌炎的预后比较
本研究基于香港全港电子医疗数据库进行回顾性队列研究,比较接种BNT162b2疫苗后28天内因心肌炎住院的≥12岁患者(104例)与疫情前病毒性心肌炎患者(762例)的180天预后。结果显示接种后心肌炎组死亡率显著低于病毒性心肌炎组(1.0% vs 11.0%,调整HR 0.08,95%CI 0.01-0.57),其他预后结局无显著差异。
要点
- 接种mRNA疫苗后心肌炎患者180天死亡率仅1.0%,显著低于病毒性心肌炎的11.0%。
- 调整后死亡风险降低92%(HR 0.08,95%CI 0.01-0.57)。
- 扩张型心肌病、心力衰竭等其它预后结局两组间无显著差异。
核心结论
- mRNA疫苗接种后心肌炎的死亡率显著低于病毒性心肌炎,预后可能较轻。
研究设计与样本
- 回顾性队列研究,使用香港全港电子公共卫生数据库与疫苗接种记录链接。
- 纳入接种BNT162b2后28天内因心肌炎住院的≥12岁患者104例,对比疫情前(2000-2019)病毒性心肌炎患者762例,随访180天。
主要发现
- 接种后心肌炎组死亡1例(1.0%),病毒性心肌炎组死亡84例(11.0%)。
- 接种后心肌炎组扩张型心肌病1例(1.0%)、心力衰竭2例(1.9%);病毒性心肌炎组分别为28例(3.7%)和93例(12.2%)。
- 调整分析显示接种后心肌炎组死亡风险降低92%(调整HR 0.08;95%CI 0.01-0.57)。
- 其他预后结局(扩张型心肌病、心力衰竭、心脏移植、出院后医疗利用)无显著差异。
临床怎么用
- 对于mRNA疫苗接种后发生心肌炎的患者,可参考此预后数据评估风险较低。
- 与病毒性心肌炎相比,疫苗接种后心肌炎的死亡风险显著更低。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Association between messenger RNA (mRNA) COVID-19 vaccines and myocarditis has aroused public concern over vaccine safety. OBJECTIVES: The goal of this study was to compare the prognosis of this condition with viral infection-related myocarditis over 180 days. METHODS: A territory-wide electronic public health care database in Hong Kong linked with population-based vaccination records was used to conduct a retrospective cohort study. Since the roll-out of BNT162b2 (Pfizer-BioNTech), patients aged ≥12 years hospitalized with myocarditis within 28 days after BNT162b2 vaccination were compared against viral infection-related myocarditis recorded before the pandemic (2000-2019), over a 180-day follow-up period (starting from diagnosis of myocarditis). All-cause mortality, heart failure, dilated cardiomyopathy, heart transplant, and postdischarge health care utilization were examined with Cox proportional hazards models. RESULTS: A total of 866 patients were included for analysis. Over the follow-up period, 1 death (1.0%) of 104 patients with postvaccination myocarditis and 84 deaths (11.0%) of 762 patients with viral infection-related myocarditis were identified. One case (1.0%) of dilated cardiomyopathy and 2 cases (1.9%) of heart failure were identified in the postvaccination group, compared with 28 (3.7%) and 93 (12.2%) in the viral infection-related myocarditis group, respectively. Adjusted analysis showed that the postvaccination myocarditis group had a 92% lower mortality risk (adjusted HR: 0.08; 95% CI: 0.01-0.57). No significant differences in other prognostic outcomes were seen. CONCLUSIONS: This study found a significantly lower rate of mortality among individuals with myocarditis after mRNA vaccination compared with those with viral infection-related myocarditis. Prognosis of this iatrogenic condition may be less severe than naturally acquired viral infection-related myocarditis.
引用
- Lai FTT, Chan EWW, Huang L, et al. Prognosis of Myocarditis Developing After mRNA COVID-19 Vaccination Compared With Viral Myocarditis. J Am Coll Cardiol. 2022. PMID: 36480967. doi:10.1016/j.jacc.2022.09.049
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。